Price
$8.72
Decreased by -5.53%
Dollar Volume
2.18 M
ADR%
8.86
Earnings Report Date (estimate)
Feb 27, 23 (-0.89)
Market Cap.
355.39 M
Shares Float
15.44 M
Shares Outstanding
40.76 M
Beta
1.83
Price / Earnings
-3.76
BPR
60.82
20D Range
8.23 11.77
50D Range
8.23 12.33
200D Range
5.82 16.31
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.87
Decreased by -117.50%
-0.77
Decreased by -12.99%
Aug 8, 22 -0.81
Decreased by -131.43%
-0.63
Decreased by -28.57%
May 9, 22 -0.60
Decreased by -25.00%
-0.71
Increased by +15.49%
Nov 11, 21 -0.61
Decreased by -69.44%
-0.48
Decreased by -27.08%
Aug 12, 21 -0.40
Increased by +90.93%
-0.43
Increased by +6.98%
May 17, 21 -0.35
Increased by +97.73%
-0.41
Increased by +14.63%
Mar 18, 21 -0.48 -0.35
Decreased by -37.14%
Nov 12, 20 -0.36 -0.36
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-35.32 M
Decreased by -43.78%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-32.92 M
Decreased by -102.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-24.53 M
Decreased by -72.95%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-83.50 M
Decreased by -344.79%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-24.57 M
Decreased by -141.29%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
-16.27 M
Decreased by -43.62%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by -100.00%
-14.19 M
Decreased by -160.08%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 1.18
Decreased by -100.00%
-18.77 M
Decreased by -141.81%
Decreased by -1.59 B%
Decreased by -248.15 M%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.